Medpace Holdings, Inc. MEDP Operating Lease Liability Payments - 2026 (Lessee)

Operating Lease Liability Payments - 2026 (Lessee) at other companies

BridgeBio PharmaBBIO

——

Royalty PharmaRPRX

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

See full

Revenue$706.6M+26.5%

Operating income$141.5M+24.6%

Net income$123.9M+8.1%

EPS (diluted)$4.28+16.6%

Balance sheet

See full

Cash & equivalents$652.7M+47.9%

Total debt$146.1M-2.8%

Total equity$598.3M+0.8%

Total assets$2.1B+12.2%

Cash flow

See full

Operating cash flow$151.8M+20.6%

CapEx$6.8M-31.8%

Free cash flow$145.0M+25.1%

Valuation

See full

Market cap$13.14B+46.8%

Enterprise value$12.64B+45.9%

P/E28.6×+7.0×

P/S4.9×+0.8×

Profitability

See full

Operating margin21%-0.1pp

Net margin17.2%-2.1pp

FCF margin26.5%+1.5pp

Returns & leverage

See full

Return on equity77.3%+11.4pp

Debt / equity0.2×0.0×

Current ratio0.8×+0.1×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medpace Holdings, Inc.'s operating lease liability payments - 2026 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Medpace Holdings, Inc.'s operating lease liability payments - 2026 (lessee)?: Medpace Holdings, Inc. (MEDP) reported operating lease liability payments - 2026 (lessee) of $18.27M in Q1 2026.
How has Medpace Holdings, Inc.'s operating lease liability payments - 2026 (lessee) changed year-over-year?: Medpace Holdings, Inc.'s operating lease liability payments - 2026 (lessee) increased by 4.6% year-over-year, from $17.47M to $18.27M.